Chanticleer
Why the Ozempic revolution matters to ASX investors
A fascinating debate around the potential for weight loss drugs to hit sleep apnoea giant ResMed raises some important questions for investors as they consider big themes such as AI and weight loss.
If artificial intelligence is the great investment theme of global markets in 2023, then the rise and rise of miracle weight-loss drugs such as Ozempic, Wegovy and Mounjaro must run a close second.
But while it can often feel like there are few ways to play the AI boom on the ASX, we have in the last few weeks seen the emergence of a fascinating example of how the weight loss revolution could touch a wide variety of stocks.
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Introducing your Newsfeed
Follow the topics, people and companies that matter to you.
Find out moreRead More
Latest In Healthcare & fitness
Fetching latest articles